These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22874771)

  • 1. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review.
    Ascierto PA; Gogas HJ; Grob JJ; Algarra SM; Mohr P; Hansson J; Hauschild A
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):149-61. PubMed ID: 22874771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
    Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
    J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma.
    Trinh VA; Zobniw C; Hwu WJ
    Expert Opin Drug Saf; 2017 Aug; 16(8):933-940. PubMed ID: 28627943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
    Kirkwood JM; Tarhini AA
    Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
    Kimyai-Asadi A; Usman A
    J Am Acad Dermatol; 2000 Oct; 43(4):708-11. PubMed ID: 11004636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapy of cutaneous melanoma.
    Mays SR; Nelson BR
    Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
    Mocellin S; Pasquali S; Rossi CR; Nitti D
    J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current management of melanoma: benefits of surgical staging and adjuvant therapy.
    McMasters KM; Swetter SM
    J Surg Oncol; 2003 Mar; 82(3):209-16. PubMed ID: 12619066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials.
    Lens MB; Dawes M
    J Clin Oncol; 2002 Apr; 20(7):1818-25. PubMed ID: 11919239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma and IFN alpha: potential adjuvant therapy.
    Bottoni U; Clerico R; Paolino G; Corsetti P; Ambrifi M; Brachini A; Richetta A; Nisticò S; Pranteda G; Calvieri S
    J Biol Regul Homeost Agents; 2014; 28(2):271-9. PubMed ID: 25001659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant interferon-alpha for melanoma revisited: news from old and new studies.
    Punt CJ; Eggermont AM
    Ann Oncol; 2001 Dec; 12(12):1663-6. PubMed ID: 11843241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy for malignant melanoma.
    Stoutenburg JP; Schrope B; Kaufman HL
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Malignant melanoma].
    Matsumoto K; Saida T
    Nihon Rinsho; 2006 Jul; 64(7):1321-6. PubMed ID: 16838651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Who benefits most from adjuvant interferon treatment for melanoma?
    Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
    Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon.
    Ascierto PA; Chiarion-Sileni V; Muggiano A; Mandalà M; Pimpinelli N; Del Vecchio M; Rinaldi G; Simeone E; Queirolo P
    J Chemother; 2014 Aug; 26(4):193-201. PubMed ID: 24621162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.
    Daud A; Soon C; Dummer R; Eggermont AM; Hwu WJ; Grob JJ; Garbe C; Hauschild A
    Expert Opin Biol Ther; 2012 Aug; 12(8):1087-99. PubMed ID: 22694288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of interferon-alpha in solid tumours: part 1.
    Decatris M; Santhanam S; O'Byrne K
    BioDrugs; 2002; 16(4):261-81. PubMed ID: 12196039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
    Ives NJ; Suciu S; Eggermont AMM; Kirkwood J; Lorigan P; Markovic SN; Garbe C; Wheatley K;
    Eur J Cancer; 2017 Sep; 82():171-183. PubMed ID: 28692949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.